[{"id":"fed51b19-c24c-4b88-8eaf-cb5c1c0f980d","acronym":"VITALIA","url":"https://clinicaltrials.gov/study/NCT03905902","created_at":"2021-01-18T19:13:43.317Z","updated_at":"2024-07-02T16:36:19.185Z","phase":"Phase 3","brief_title":"DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma","source_id_and_acronym":"NCT03905902 - VITALIA","lead_sponsor":"SOTIO a.s.","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • DCVAC/OvCa"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/16/2021","study_completion_date":" 08/16/2021","last_update_posted":"2021-12-23"},{"id":"37fc10b8-be9b-48ab-b336-85a791a04e00","acronym":"","url":"https://clinicaltrials.gov/study/NCT04834544","created_at":"2021-04-08T13:52:21.892Z","updated_at":"2024-07-02T16:36:30.786Z","phase":"Phase 2","brief_title":"A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care","source_id_and_acronym":"NCT04834544","lead_sponsor":"Peking University Third Hospital","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DCVAC/OvCa"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 04/19/2021","start_date":" 04/19/2021","primary_txt":" Primary completion: 10/20/2024","primary_completion_date":" 10/20/2024","study_txt":" Completion: 04/20/2027","study_completion_date":" 04/20/2027","last_update_posted":"2021-05-03"}]